title: Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement.
abstract: Multiple myeloma is a neoplastic plasma cell dyscrasia that on a yearly basis affects nearly 17,000 individuals and kills more than 11,000. Although no cure exists, many effective treatments are available that prolong survival and improve the quality of life of patients with this disease. The purpose of this consensus is to offer a simplified, evidence-based algorithm of decision making for patients with newly diagnosed myeloma. In cases in which evidence is lacking, our team of 18 Mayo Clinic myeloma experts reached a consensus on what therapy could generally be recommended. The focal point of our strategy revolves around risk stratification. Although a multitude of risk factors have been identified throughout the years, including age, tumor burden, renal function, lactate dehydrogenase, beta2-microglobulin, and serum albumin, our group has now recognized and endorsed a genetic stratification and patient functional status for treatment.
authors.affiliation: Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA. dispenzieri.angela@mayo.edu
authors.forename: Angela
authors.initials: A
authors.lastname: Dispenzieri
authors.forename: S Vincent
authors.initials: SV
authors.lastname: Rajkumar
authors.forename: Morie A
authors.initials: MA
authors.lastname: Gertz
authors.forename: Rafael
authors.initials: R
authors.lastname: Fonseca
authors.forename: Martha Q
authors.initials: MQ
authors.lastname: Lacy
authors.forename: P Leif
authors.initials: PL
authors.lastname: Bergsagel
authors.forename: Robert A
authors.initials: RA
authors.lastname: Kyle
authors.forename: Philip R
authors.initials: PR
authors.lastname: Greipp
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Witzig
authors.forename: Craig B
authors.initials: CB
authors.lastname: Reeder
authors.forename: John A
authors.initials: JA
authors.lastname: Lust
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Russell
authors.forename: Suzanne R
authors.initials: SR
authors.lastname: Hayman
authors.forename: Vivek
authors.initials: V
authors.lastname: Roy
authors.forename: Shaji
authors.initials: S
authors.lastname: Kumar
authors.forename: Steven R
authors.initials: SR
authors.lastname: Zeldenrust
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Dalton
authors.forename: A Keith
authors.initials: AK
authors.lastname: Stewart
mesh_terms: D000465:Algorithms; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003657:Decision Making; D019317:Evidence-Based Medicine; D006801:Humans; D009101:Multiple Myeloma / Q000235:genetics / Q000628:therapy*; D010166:Palliative Care; D012307:Risk Factors; D033581:Stem Cell Transplantation
chemical_list: D000970:Antineoplastic Agents